Key facts
- This page summarizes Brian McKelligon's Form 4 filing for Akoya Biosciences, Inc. (AKYA).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 01 Mar 2024, 21:21.
Brian McKelligon - 22 Feb 2024 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- AKYA
- Reported as of
- 22 Feb 2024
- Net transaction value
- -$61,771
- SEC form
- 4
- Accepted by SEC
- 01 Mar 2024, 21:21:06 UTC
- Prior SEC filing
- 20 Dec 2023
- Next SEC filing
- 22 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian McKelligon
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian McKelligon filed Form 4 for Akoya Biosciences, Inc. (AKYA) on 01 Mar 2024.
Change
- Previous filing in this sequence was filed on 20 Dec 2023.
- Current net transaction value: -$61,771.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AKYA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +87,500
- Change %
- +57%
- Price
- $0.000000
- Shares after
- 240,063
- Date
- 22 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
AKYA
transaction
Common Stock
Tax liability
- Transaction value
- $49,416
- Shares
- -8,195
- Change %
- -3.4%
- Price
- $6.03
- Shares after
- 231,868
- Date
- 01 Mar 2024
- Ownership
- Direct
AKYA
transaction
Common Stock
Tax liability
- Transaction value
- $12,355
- Shares
- -2,049
- Change %
- -1.9%
- Price
- $6.03
- Shares after
- 103,506
- Date
- 01 Mar 2024
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AKYA
transaction
Derivative
Employee Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +175,000
- Change %
- Price
- $0.000000
- Shares after
- 175,000
- Date
- 22 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 175,000
- Exercise price
- $5.35
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The restricted stock units shall vest in four (4) equal annual installments beginning on March 1, 2025, and annually thereafter until fully vested.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of Akoya Biosciences, Inc. common stock.
Footnote F3
Represents shares withheld to cover taxes on a restricted stock unit award previously granted February 23, 2023, which vest in four (4) equal annual installments beginning on March 1, 2024, and annually thereafter until fully vested.
Footnote F4
The options shall vest as follows: twenty-five percent (25%) shall vest on February 22, 2025 with the remainder vesting in 36 equal monthly installments beginning on March 22, 2025.